Structure Therapeutics has touted the 16% weight loss seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3.
- Home |
- Structure touts 16% weight loss for aleniglipron as ‘highest efficacy’ for an oral GLP-1 yet
Structure touts 16% weight loss for aleniglipron as ‘highest efficacy’ for an oral GLP-1 yet
- March 16, 2026
Recent Posts
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
- Energy Transfer expands Delaware basin footprint with $2.625 billion deal
- ConocoPhillips’ chairman sees oil price floor rising towards $70/bbl
